In re Sage Therapeutics, Inc. Securities Litigation

CourtDistrict Court, S.D. New York
DecidedDecember 2, 2024
Docket1:24-cv-06511
StatusUnknown

This text of In re Sage Therapeutics, Inc. Securities Litigation (In re Sage Therapeutics, Inc. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Sage Therapeutics, Inc. Securities Litigation, (S.D.N.Y. 2024).

Opinion

USONUITTEHDE RSTNA DTIESST RDIICSTT ROIFC TN ECWOU YROTR K -------------------------------------------------------------- X : DARREN KORVER, : : Plaintiff, : 24 Civ. 6511 (LGS) : -against- : ORDER : SAGE THERAPEUTICS, INC., et al., : : Defendants. : -------------------------------------------------------------- X

LORNA G. SCHOFIELD, District Judge: This action was originally commenced by Darren Korver, on behalf of himself and all others similarly situated, against Defendants Sage Therapeutics, Inc. (“Sage”) and certain of its officers, alleging violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended by the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), and Rule 10b-5 promulgated under section 10(b), 17 C.F.R. § 240.10b-5. This order grants the unopposed motion of Steamfitters Local 449 Pension & Retirement Security Funds and Trust of the Retirement System of the UPR (collectively, the “Pension Funds”) for appointment as lead plaintiffs and appointment of Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) and Abraham, Fruchter & Twersky, LLP (“AF&T”) as co-lead counsel, pursuant to section 21D(a)(3)(B) of the Exchange Act, 15 U.S.C. § 78u-4(a)(3)(B), as amended by the PSLRA. I. DISCUSSION A. Appointment of Lead Plaintiff On August 28, 2024, statutory notice was published in a national wire service. On October 28, 2024, Mark Friedman, Kapila Wijayatilleke, Edward Freedman and the Pension Funds each filed timely motions for appointment as lead plaintiff and approval of lead counsel. On October 30, 2024, Kapila Wijayatilleke filed a notice of withdrawal of his motion. On November 11, 2024, Edward Freedman filed a notice of withdrawal of his motion. On November 22, 2024, Mark Friedman filed notice of withdrawal of his motion, leaving only the Pension Funds’ motion. 1. Applicable Law The PSLRA governs the appointment of a lead plaintiff in a private securities class action. Under the PSLRA, the Court must adopt a rebuttable presumption that the most adequate plaintiff is the person or group of persons that: (aa) has either filed the complaint or made a motion in response to a notice under subparagraph (A)(i); (bb) in the determination of the court, has the largest financial interest in the relief sought by the class; and (cc) otherwise satisfies the requirements of Rule 23 of the Federal Rules of Civil Procedure.

15 U.S.C. § 78u-4(a)(3)(B)(iii)(I). Once the presumption is established, it may be rebutted only with proof that the presumptive lead plaintiff “will not fairly and adequately protect the interests of the class” or “is subject to unique defenses that render such plaintiff incapable of adequately representing the class.” 15 U.S.C. § 78u-4(a)(3)(B)(iii)(II). 2. Presumptive Lead Plaintiff a. Notice and Timeliness The PSLRA requires that a plaintiff who files a securities class action must publish, “in a widely circulated national business-oriented publication or wire service, a notice” advising members of the purported plaintiff class “of the pendency of the action, the claims asserted therein, and the purported class period” and that “any member of the purported class may move the court to serve as lead plaintiff of the purported class.” 15 U.S.C. § 78u-4(a)(3)(A)(i). In evaluating the appointment of a lead plaintiff under the PLSRA, “courts have an independent duty to scrutinize the published notice and ensure that the notice comports with the objectives of the PSLRA.” City of Omaha Police & Firefighters Ret. Sys. v. Cognyte Software Ltd., No. 23 Civ. 1769, 2023 WL 6458930, at *2 (S.D.N.Y. Oct. 4, 2023). Here, statutory notice was timely published on August 28, 2024. The Pension Funds timely filed their motion for appointment as lead plaintiffs on October 28, 2024. As such, they have satisfied the first requirement to become the presumptive lead plaintiffs. b. Financial Interest The second statutory requirement for the presumption is “the largest financial interest in the relief sought by the class.” 15 U.S.C. § 78u-4(a)(3)(B)(iii)(I)(bb). The Pension Funds purchased 30,828 shares of Sage and collectively suffered approximately $247,084 in losses. Each fund individually, however, has a smaller financial stake: the Trust of the Retirement System of the UPR purchased a total of 6,065 shares and lost $145,742.32, and the Steamfitters Local 449 Pension &

Retirement Security Funds purchased 24,763 shares and lost $101,341.71. The PSLRA “permits multiple putative class members to be appointed as lead plaintiffs.” Khunt v. Alibaba Grp. Holding Ltd., 102 F. Supp. 3d 523, 532 (S.D.N.Y. 2015) (citing 15 U.S.C. § 78u-4(a)(3)(B)(i)); accord Baxter v. Mongodb, Inc., No. 24 Civ. 5191, 2024 WL 4753605, at *3 (S.D.N.Y. Nov. 12, 2024). “Courts permit unrelated investors to move for appointment as lead plaintiff, and aggregate their financial interests, on a case-by-case basis.” Armstrong v. Med. Props. Tr., Inc., No. 23 Civ. 8597, 2024 WL 3784445, at *3 (S.D.N.Y. Aug. 13, 2024); Varghese v. China Shenghuo Pharm. Holdings, Inc., 589 F. Supp. 2d 388, 392 (S.D.N.Y. 2008). The PSLRA does not define what a “group” can or should be, nor how its “members” must be related to one another. See

Varghese, 589 F. Supp. 2d at 392. Groups with unrelated members must provide evidence that they will function cohesively and thus best serve the class. Id. Courts have considered factors such as “(1) the existence of a pre-litigation relationship between group members; (2) involvement of the

1 Unless otherwise indicated, in quoting cases, all internal quotation marks, alterations, emphases, footnotes and citations are omitted. group members in the litigation thus far; (3) plans for cooperation; (4) the sophistication of its members; and (5) whether the members chose outside counsel, and not vice versa.” Id. Courts will reject a group of unrelated investors if the group “has not provided sufficient evidence that it will function cohesively, and has only provided ‘conclusory assurances’ that call into question whether it can manage th[e] litigation effectively.” Micholle v. Ophthotech Corp., No. 17 Civ. 1758, 2018 WL 1307285, at *9 (S.D.N.Y. Mar. 13, 2018); accord Armstrong, 2024 WL 3784445, at *3. The Pension Funds are a permissible group, as they satisfy the factors described in Varghese. First, the Pension Funds’ declaration in support of their motion does not describe a pre- litigation relationship between the two funds. “This is a negative factor but not disqualifying by itself.” Chauhan v. Intercept Pharms., No. 21 Civ. 00036, 2021 WL 235890, at *4 (S.D.N.Y. Jan.

25, 2021). Their declaration describes at a high-level joint involvement by the funds in preparing for the motion and joint consideration of their cooperative approach to the litigation.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Varghese v. China Shenghuo Pharmaceutical Holdings, Inc.
589 F. Supp. 2d 388 (S.D. New York, 2008)
Barrows v. Becerra
24 F.4th 116 (Second Circuit, 2022)
Khunt v. Alibaba Group Holding Ltd.
102 F. Supp. 3d 523 (S.D. New York, 2015)
In re Donnkenny Inc. Securities Litigation
171 F.R.D. 156 (S.D. New York, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
In re Sage Therapeutics, Inc. Securities Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-sage-therapeutics-inc-securities-litigation-nysd-2024.